Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors
Искоренение суицида в его основе: доклинические предпосылки и клинические данные об эффективности кетамина в лечении суицидального поведения
2018-09-23
SCID: 54.1/2pfqhfr7
Discuss with AI
NMDA receptor antagonismketaminemTOR signalingmood disorderssuicidal ideation
Figures from the paper
Abstract (AI)
Despite the continuous advancement in neurosciences as well as in the knowledge of human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World Health Organization (WHO) has established that one million people die by suicide every year, with the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior is how difficult it is for healthcare professionals to predict. However, recent evidence in genomic studies has pointed out the essential role that genetics could play in influencing person’s suicide risk. Combining genomic and clinical risk assessment approaches, some studies have identified a number of biomarkers for suicidal ideation, which are involved in neural connectivity, neural activity, mood, as well as in immune and inflammatory response, such as the mammalian target of rapamycin (mTOR) signaling. This interesting discovery provides the neurobiological bases for the use of drugs that impact these specific signaling pathways in the treatment of suicidality, such as ketamine. Ketamine, an N-methyl-d-aspartate glutamate (NMDA) antagonist agent, has recently hit the headlines because of its rapid antidepressant and concurrent anti-suicidal action. Here we review the preclinical and clinical evidence that lay the foundations of the efficacy of ketamine in the treatment of suicidal ideation in mood disorders, thereby also approaching the essential question of the understanding of neurobiological processes of suicide and the potential therapeutics.
Key Findings
1
Genomic and clinical risk-assessment studies identify biomarkers of suicidal ideation involving neural connectivity, neural activity, mood, immune responses, and inflammation.
2
Ketamine, an NMDA receptor antagonist, demonstrates rapid antidepressant and concurrent anti-suicidal effects in mood disorders.
3
Preclinical and clinical evidence supports ketamine’s efficacy for reducing suicidal ideation, while contributing to understanding suicide-related neurobiology.
4
Suicide risk remains difficult to predict, underscoring the potential value of combining genomic biomarkers with clinical assessment.
5
The mTOR signaling pathway is highlighted as a neurobiological mechanism potentially linking biomarkers to suicidal behavior and treatment targets.
Research Object
Suicidal ideation and behaviors in mood disorders
Research Subject
The preclinical and clinical efficacy of ketamine and its neurobiological mechanisms in reducing suicidality
Publication Details
Publication Date
2018-09-23
Journal
Publisher
ISSN
Cited by
179
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest